Tremor and dopamine agonists

Neurology

Volumn 58, Issue 4 SUPPL. 1, 2002, Pages

  Elble, Rodger J ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine agonists; Levodopa; Surgery; Tremor

Indexed keywords

AMANTADINE; BENZATROPINE; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; PROPRANOLOL; ROPINIROLE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL; ANTIPARKINSON AGENT;

COGNITIVE DEFECT; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG RESPONSE; ESSENTIAL TREMOR; HUMAN; NEUROPATHOLOGY; NEUROSURGERY; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TREMOR; PATHOPHYSIOLOGY;

ANTIPARKINSON AGENTS; DIAGNOSIS, DIFFERENTIAL; DOPAMINE AGONISTS; HUMANS; LEVODOPA; PARKINSON DISEASE; TREMOR;

EID: 0037176819     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.58.suppl_1.s57     Document Type: Review

References (49)

1. Re-emergent tremor of Parkinson's disease
2. Physiology of MPTP tremor
3. MPTP-induced parkinsonism and tremor
4. Central motor loop oscillations in parkinsonian resting tremor revealed by magnetoencephalography
5. Single unit analysis of the human ventral thalamic nuclear group. Tremor-related activity in functionally identified cells
6. The role of the thalamus and basal ganglia in parkinsonian tremor
7. Dynamics of tremor-related oscillations in the human globus pallidus: A single case study
8. Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease
9. High-frequency synchronization of neuronal activity in the subthalamic nucleus of parkinsonian patients with limb tremor
10. Single-unit analysis of the pallidum, thalamus and subthalamic nucleus in parkinsonian patients
11. Subthalamic neuron activity related to tremor and movement in Parkinson's disease
12. Function of the cerebellum in parkinsonian rest tremor and Holmes' tremor
13. The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism
14. Classification of tremors
15. Diagnostic criteria for essential tremor and differential diagnosis
16. Significance of parkinsonian manifestations in essential tremor
17. Isolated tremor and disruption of the nigrostriatal dopaminergic system: An 18F-dopa PET study
18. How common is the most common adult movement disorder? Estimates of the prevalence of essential tremor throughout the world
19. Risk of tremor and impairment from tremor in relatives of patients with essential tremor: A community-based family study
20. Tremor in ostensibly normal elderly people
21. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts
22. Pharmacologic treatment of parkinsonian tremor
23. An open multicenter trial of Sinemet CR in levodopa-naive Parkinson's disease patients
24. Benztropine versus clozapine for the treatment of tremor in Parkinson's disease
25. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease
26. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study
27. A randomised controlled study of bromocriptine versus levodopa in previously untreated parkinsonian patients: A 3-year follow-up
28. Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study
29. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease
30. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease
31. Pramipexole in the treatment of advanced Parkinson's disease
32. Adjuvant therapy of parkinsonian tremor
33. Three-dimensional measurement of essential tremor
34. Cortical myoclonus in levodopa-responsive parkinsonism
35. Amantadine for levodopa-induced dyskinesias: A 1-year follow-up study
36. The antiparkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way
37. Selegiline and levodopa in early or moderately advanced Parkinson's disease: A double-blind controlled short- and long-term study
38. Clozapine in Parkinson's disease tremor. Effects of acute and chronic administration
39. Gabapentin for parkinsonism: A double-blind, placebo-controlled, crossover trial
40. Costs of drug treatment in Parkinson's disease
41. Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
42. Hallucinosis in idiopathic Parkinson's disease
43. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease
44. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study
45. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: A five-year follow up
46. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial
47. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa